Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
A Global Imatinib and Nilotinib Pregnancy Exposure Registry
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Women exposed to any dose of Gleevec/Glivec or Tasigna during pregnancy or within 6 months prior to conception
Provide sufficient evidence to confirm that exposure occurred during pregnancy or within 6 months prior to exposure.
Be at least 18 years of age
Reside in a country supported by the Registry
Cases that do not meet the eligibility criteria are deemed ineligible, including paternal exposures
Other protocol-defined inclusion/exclusion criteria may apply